# US 2024/0116847 A1 · Treprostinil derivatives and compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0116847 A1
- Document ID: US20240116847A1
- Status: Published application
- Kind: A1
- Application number: 18/370,574
- Filed: 2023-09-20
- Published: 2024-04-11
- Earliest claimed: 2015-06-17
- Assignees: Corsair Pharma, Inc.
- Applicants: Corsair Pharma, Inc.
- Inventors: Xiaoming ZHANG; Meenakshi S. VENKATRAMAN; Cyrus K. BECKER
- Web page: https://patentgrep.com/patent/US20240116847A1

## CPC

- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07C 69/734: Ethers
- A61K 9/7023: {Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006)}
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07C 53/136: containing condensed ring systems
- C07C 59/11: containing rings
- C07C 59/13: containing rings
- C07C 69/28: esterified with dihydroxylic compounds
- C07C 69/675: of saturated hydroxy-carboxylic acids
- C07C 69/68: Lactic acid esters
- C07C 69/708: Ethers
- C07C 69/712: the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
- C07C 69/74: Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C 69/75: of acids with a six-membered ring
- C07C 69/96: Esters of carbonic or haloformic acids
- C07D 305/08: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
- C07D 307/24: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 307/30: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 309/08: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07C 2601/02: with a three-membered ring
- C07C 2601/04: with a four-membered ring
- C07C 2601/08: the ring being saturated
- C07C 2601/14: The ring being saturated
- C07C 2603/14: Benz[f]indenes; Hydrogenated benz[f]indenes
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A method of promoting vasodilation, inhibiting platelet activation or aggregation, inhibiting thrombus formation, stimulating thrombolysis, inhibiting atherogenesis, inhibiting cell proliferation, promoting endothelial cell membrane remodeling, reducing inflammation, or providing cytoprotection, comprising administering to a subject in need of treatment a therapeutically effective amount of a compound selected from the group consisting of:
or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, polymorph or stereoisomer thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the compound is administered orally.

### Claim 21 (depends on 19)

The method of claim 19, wherein the compound is administered parenterally.

### Claim 22 (depends on 21)

The method of claim 21, wherein the compound is administered intravenously or subcutaneously.

### Claim 23 (depends on 19)

The method of claim 19, wherein the compound is administered topically.

### Claim 24 (depends on 23)

The method of claim 23, wherein the compound is administered transdermally or pulmonarily by inhalation.

### Claim 25

A method of treating pulmonary arterial hypertension, comprising administering to a subject in need of treatment a therapeutically effective amount of a treprostinil derivative selected from the group consisting of:
or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, polymorph or stereoisomer thereof, in combination with an endothelin receptor antagonist or/and a phosphodiesterase type 5 (PDE5) inhibitor.

### Claim 26 (depends on 25)

The method of claim 25, wherein the endothelin receptor antagonist is an antagonist of ETA or an antagonist of both ETA and ETB.

### Claim 27 (depends on 25)

The method of claim 25, wherein the endothelin receptor antagonist is ambrisentan, bosentan or Actelion-1.

### Claim 28 (depends on 25)

The method of claim 25, wherein the PDE5 inhibitor is sildenafil or tadalafil.

### Claim 29 (depends on 25)

The method of claim 25, wherein the treprostinil derivative is administered orally.

### Claim 30 (depends on 25)

The method of claim 25, wherein the treprostinil derivative is administered parenterally.

### Claim 31 (depends on 30)

The method of claim 30, wherein the treprostinil derivative is administered intravenously or subcutaneously.

### Claim 32 (depends on 25)

The method of claim 25, wherein the treprostinil derivative is administered topically.

### Claim 33 (depends on 32)

The method of claim 32, wherein the treprostinil derivative is administered transdermally or pulmonarily by inhalation.
